Japan Pharma Market Evolves Towards Generics And Innovative Products
CPhI Japan 2015 opens as new foreign entrants and generics drive market value to US$166 billion by 2023
Amsterdam, 13 April 2015: CPhI Japan, organised by UBM EMEA, will take place at the Big Sight Exhibition Centre, Tokyo, Japan, 22nd-24th April. Now in its 14th consecutive year, 2015 will see the event co-located with ICSE, BioPh, InnoPack and P-MEC in conjunction LABWorld.
The global pharma event returns to Japan – the world’s second and Asia’s number one pharma market – as the regional industry is increasingly looking to international partners for collaborations. Examining the market, CPhI forecasts that the next wave of Japanese growth will be driven primarily by the recent uptake of generics and the pharma economy will soar to a value of US$166 billion by 2023. Collectively, this means that the Japanese pharma economy is shifting away from being a domestically dominated market, with companies now utilising a more open, internationally collaborative approach.
Within the country there is a duel strategy emerging, with big pharma still maintaining the vast majority of the market through high-value, innovative drugs. In fact, this focus on big pharma has resulted in Japan’s status as the third largest producer of patented drugs. Over the next few years, Japanese companies will be responsible for some of the biggest breakthroughs in healthcare. The Government support for the industry and its reimbursement model continues to makes this a hugely attractive market for the development of new drugs.
However, this dynamic is shifting as we see an increased use of generic drugs which will act as the key contributor for future growth and will gradually help reduce the overall healthcare cost for the country, presenting opportunities for a new type of market entrant.
CPhI Japan 2015 provides valuable insights into the country’s market rules, regulations and trends. Therefore, it plays a crucial role in facilitating new business opportunities for both domestic and international companies.
“CPhI Japan is an event that is full of potential to expand existing business, explore new markets, learn the latest trends in the industry and to learn about the business culture,” said Ashish Trivedi, Head of Oncology Project Management at Dishman Group, an Indian company benefiting from recent market changes.
Moreover, the event is now the largest pharmaceuticals gathering in Japan, with an estimated 17,500+ visitors and over 500 exhibiting companies expected, building on last year’s numbers of 17,275 and 400 respectively. Reflecting the increasing internationalisation of the market, CPhI Japan is also expanding its global presence, with 30+ countries due to be represented in 2015.
2015 CPhI Japan highlights include:
• Extensive program of seminars, conferences and workshops across the 3-day event
• Mobile app showing exhibitor list, floor plan and schedule on the go
• Buyer Appointment System enabling buyers to discover and set up meetings with new suppliers in an effective and efficient way
“Japan is the second largest pharma market in the world and remains incredibly important to the pharmaceutical industry with many new patented products being developed within the country – it’s truly a hotbed of innovation. In the future there will also be huge opportunity regarding Japan’s lower consumption of generics when compared to the majority of major markets, which is hugely advantageous for big pharma who have capitalised on this over the last decade.” Erik Heemskerk, Brand Director at CPhI.
Register online for CPhI Japan now – free of charge – through: https://www.ubmjapan-group.com/cphi/en/form/visitor_regist.php
Notes to editors
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, Southeast Asia, Istanbul and Russia, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.
For more information visit: www.cphi.com
The UBM EMEA annual schedule of Pharmaceutical events includes; CPhI, P-MEC and Innopack South East Asia (08-10 April, 2015 at the Jakarta International Expo- Jakarta, Indonesia); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan (22-24 April, 2015 at the Big Sight Exhibition Centre- Tokyo). CPhI Russia and IPhEB (27-29 April, 2015 at the VVC, Pavilion Nr 75, Moscow Russia); CPhI Istanbul (3-5 June, 2015, at the Lutfi Kirdar Convention and Exhibition Centre- Turkey); CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (24-26 June, 2015 at SNIEC- Shanghai, China); CPhI, ICSE Korea (7-9 September, 2015 at the COEX- Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (13-15 October 2015, IFEMA- Feria de Madrid, Spain) CPhI, P-MEC, ICSE and BioPh India (1-3 December, 2015 at the Bombay Convention and Exhibition Centre, Mumbai, India).
About UBM EMEA
UBM EMEA connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com
Help employers find you! Check out all the jobs and post your resume.
Amsterdam, 13 April 2015: CPhI Japan, organised by UBM EMEA, will take place at the Big Sight Exhibition Centre, Tokyo, Japan, 22nd-24th April. Now in its 14th consecutive year, 2015 will see the event co-located with ICSE, BioPh, InnoPack and P-MEC in conjunction LABWorld.
The global pharma event returns to Japan – the world’s second and Asia’s number one pharma market – as the regional industry is increasingly looking to international partners for collaborations. Examining the market, CPhI forecasts that the next wave of Japanese growth will be driven primarily by the recent uptake of generics and the pharma economy will soar to a value of US$166 billion by 2023. Collectively, this means that the Japanese pharma economy is shifting away from being a domestically dominated market, with companies now utilising a more open, internationally collaborative approach.
Within the country there is a duel strategy emerging, with big pharma still maintaining the vast majority of the market through high-value, innovative drugs. In fact, this focus on big pharma has resulted in Japan’s status as the third largest producer of patented drugs. Over the next few years, Japanese companies will be responsible for some of the biggest breakthroughs in healthcare. The Government support for the industry and its reimbursement model continues to makes this a hugely attractive market for the development of new drugs.
However, this dynamic is shifting as we see an increased use of generic drugs which will act as the key contributor for future growth and will gradually help reduce the overall healthcare cost for the country, presenting opportunities for a new type of market entrant.
CPhI Japan 2015 provides valuable insights into the country’s market rules, regulations and trends. Therefore, it plays a crucial role in facilitating new business opportunities for both domestic and international companies.
“CPhI Japan is an event that is full of potential to expand existing business, explore new markets, learn the latest trends in the industry and to learn about the business culture,” said Ashish Trivedi, Head of Oncology Project Management at Dishman Group, an Indian company benefiting from recent market changes.
Moreover, the event is now the largest pharmaceuticals gathering in Japan, with an estimated 17,500+ visitors and over 500 exhibiting companies expected, building on last year’s numbers of 17,275 and 400 respectively. Reflecting the increasing internationalisation of the market, CPhI Japan is also expanding its global presence, with 30+ countries due to be represented in 2015.
2015 CPhI Japan highlights include:
• Extensive program of seminars, conferences and workshops across the 3-day event
• Mobile app showing exhibitor list, floor plan and schedule on the go
• Buyer Appointment System enabling buyers to discover and set up meetings with new suppliers in an effective and efficient way
“Japan is the second largest pharma market in the world and remains incredibly important to the pharmaceutical industry with many new patented products being developed within the country – it’s truly a hotbed of innovation. In the future there will also be huge opportunity regarding Japan’s lower consumption of generics when compared to the majority of major markets, which is hugely advantageous for big pharma who have capitalised on this over the last decade.” Erik Heemskerk, Brand Director at CPhI.
Register online for CPhI Japan now – free of charge – through: https://www.ubmjapan-group.com/cphi/en/form/visitor_regist.php
Notes to editors
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, Southeast Asia, Istanbul and Russia, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.
For more information visit: www.cphi.com
The UBM EMEA annual schedule of Pharmaceutical events includes; CPhI, P-MEC and Innopack South East Asia (08-10 April, 2015 at the Jakarta International Expo- Jakarta, Indonesia); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan (22-24 April, 2015 at the Big Sight Exhibition Centre- Tokyo). CPhI Russia and IPhEB (27-29 April, 2015 at the VVC, Pavilion Nr 75, Moscow Russia); CPhI Istanbul (3-5 June, 2015, at the Lutfi Kirdar Convention and Exhibition Centre- Turkey); CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (24-26 June, 2015 at SNIEC- Shanghai, China); CPhI, ICSE Korea (7-9 September, 2015 at the COEX- Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (13-15 October 2015, IFEMA- Feria de Madrid, Spain) CPhI, P-MEC, ICSE and BioPh India (1-3 December, 2015 at the Bombay Convention and Exhibition Centre, Mumbai, India).
About UBM EMEA
UBM EMEA connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com
Help employers find you! Check out all the jobs and post your resume.